Archive: https://archive.today/Emrbw
From the post:
>In a small trial, Mass General Brigham researchers have found that a drug designed to treat celiac disease supported a more rapid return to normal activities for patients following COVID.
Multisystem inflammatory syndrome in children (MIS-C) is a rare but serious condition that can occur after a COVID-19 infection, presenting as high fevers, gastrointestinal symptoms, and life-threatening cardiac injury. A small, randomized clinical trial led by Mass General Brigham investigators found the oral drug larazotide—an experimental drug originally designed to treat celiac disease—was both safe and effective in treating children with MIS-C.
Archive: https://archive.today/Emrbw
From the post:
>>In a small trial, Mass General Brigham researchers have found that a drug designed to treat celiac disease supported a more rapid return to normal activities for patients following COVID.
Multisystem inflammatory syndrome in children (MIS-C) is a rare but serious condition that can occur after a COVID-19 infection, presenting as high fevers, gastrointestinal symptoms, and life-threatening cardiac injury. A small, randomized clinical trial led by Mass General Brigham investigators found the oral drug larazotide—an experimental drug originally designed to treat celiac disease—was both safe and effective in treating children with MIS-C.